BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy
BioMark Diagnostics (OTCQB: BMKDF) announced support for the 2026–2035 Pan-Canadian Lung Cancer Action Plan, aligning its next‑generation metabolomics and AI liquid biopsy approach with the plan's goal to reduce lung cancer mortality by 30% over the next decade. The company highlighted clinical results showing AI‑enabled biomarker testing can identify more early‑stage cancers, including in non‑smokers, and said its blood‑based tests can complement low‑dose CT screening and help expand access in underserved and remote communities.
BioMark invited partnerships with national and provincial healthcare providers and community organizations to scale early detection across Canada.
BioMark Diagnostics (OTCQB: BMKDF) ha annunciato supporto al Piano d'Azione Pan-Canadian per il tumore al polmone 2026–2035, allineando il suo approccio di metabolomica di nuova generazione e biopsia liquida AI con l'obiettivo del piano di ridurre la mortalità per tumore al polmone del 30% nel prossimo decennio. L'azienda ha evidenziato risultati clinici che mostrano che i test biomarcatori abilitati dall'IA possono identificare più tumori in stadio precoce, anche tra i non fumatori, e ha affermato che i suoi test basati sul sangue possono integrare lo screening con TAC a bassa dose e contribuire ad ampliare l'accesso in comunità svantaggiate e remote. BioMark ha invitato partnership con fornitori nazionali e provinciali di assistenza sanitaria e organizzazioni comunitarie per scalare la rilevazione precoce in tutto il Canada.
BioMark ha invitato partnership con fornitori nazionali e provinciali di assistenza sanitaria e organizzazioni comunitarie per scalare la rilevazione precoce in tutto il Canada.
BioMark Diagnostics (OTCQB: BMKDF) anunció su apoyo al Plan Pan-Canadiense de Acción contra el Cáncer de Pulmón 2026–2035, alineando su enfoque de metabolómica de próxima generación y biopsia líquida con IA con el objetivo del plan de reducir la mortalidad por cáncer de pulmón en un 30% durante la próxima década. La empresa destacó resultados clínicos que muestran que las pruebas de biomarcadores habilitadas por IA pueden identificar más cánceres en etapas tempranas, incluso en no fumadores, y dijo que sus pruebas basadas en sangre pueden complementar la detección por TAC de dosis baja y ayudar a ampliar el acceso en comunidades desatendidas y remotas. BioMark invitó a asociaciones con proveedores de atención sanitaria nacionales y provinciales y organizaciones comunitarias para escalar la detección temprana en Canadá.
BioMark Diagnostics (OTCQB: BMKDF)가 2026–2035년 팬 캐나다 폐암 행동 계획에 대한 지지를 발표했고, 차세대 대사체학과 AI 액체 생검 접근법을 계획의 목표인 향후 10년간 폐암 사망률 30% 감소에 맞추었습니다. 이 회사는 AI 기반 바이오마커 테스트가 초기 단계 암을 더 많이 식별할 수 있음을 보여주는 임상 결과를 강조했고, 혈액 기반 검사가 저선량 CT 선별을 보완하고 취약하고 원격 지역의 접근성을 확대하는 데 도움을 줄 수 있다고 말했습니다. BioMark는 캐나다 전역의 조기 발견을 확대하기 위해 전국적 및 주 차원의 보건의료 제공자와 지역사회 단체와의 파트너십을 초청했습니다.
BioMark Diagnostics (OTCQB: BMKDF) a annoncé son soutien au Plan d'action pan-canadien contre le cancer du poumon 2026–2035, alignant son approche de métabolomique de nouvelle génération et de biopsie liquide assistée par IA sur l'objectif du plan de réduire la mortalité par cancer du poumon de 30% au cours de la prochaine décennie. L'entreprise a mis en avant des résultats cliniques montrant que les tests de biomarqueurs activés par l'IA peuvent identifier davantage de cancers à un stade précoce, y compris chez les non-fumeurs, et a déclaré que ses tests sanguins peuvent compléter le dépistage par Tomodensitométrie (CT) à faible dose et aider à étendre l'accès dans les communautés défavorisées et éloignées. BioMark a invité des partenariats avec des prestataires de soins de santé nationaux et provinciaux et des organisations communautaires pour accélérer le dépistage précoce à travers le Canada.
BioMark Diagnostics (OTCQB: BMKDF) kündigte Unterstützung für den pan-kanadischen Aktionsplan gegen Lungenkrebs 2026–2035 an und richtet seinen Ansatz der Next-Generation-Metabolomik und KI-Bluttest an das Ziel des Plans aus, die Lungenkrebs-Mortalität in den nächsten zehn Jahren um 30% zu senken. Das Unternehmen hob klinische Ergebnisse hervor, die zeigen, dass KI-gestützte Biomarker-Tests mehr Krebs im Frühstadium identifizieren können, auch bei Nichtrauchern, und sagte, dass seine blutbasierten Tests die Low-Dose-CT-Screening ergänzen und dazu beitragen können, den Zugang in unterversorgten und abgelegenen Gemeinschaften zu erweitern. BioMark lud Partnerschaften mit nationalen und provinziellen Gesundheitsdienstleistern und Gemeinschaftsorganisationen ein, die Früherkennung in ganz Kanada auszuweiten.
BioMark Diagnostics (OTCQB: BMKDF) أعلنت عن دعمها لخطة العمل الكندية الشاملة لسرطان الرئة 2026–2035، مع تواؤم نهجها الجديد للمتابوليومك وقراءة سائل الدم بالذكاء الاصطناعي مع هدف الخطة في تقليل وفيات سرطان الرئة بنسبة 30% خلال العقد القادم. سلطت الشركة الضوء على نتائج سريرية تُظهر أن الاختبار باستخدام مؤشرات حيوية مُمكَّنة من الذكاء الاصطناعي يمكن أن يحدد مزيداً من السرطانات في مراحل مبكرة، بما في ذلك بين غير المدخنين، وقالت إن اختبارات الدم يمكن أن تكمل فحص التصوير المقطعي المحوسب منخفض الجرعة وتساعد في توسيع الوصول في المجتمعات المحرومة والبعيدة. دعت BioMark إلى شراكات مع مقدمي الرعاية الصحية الوطنيين والإقليميين ومنظمات المجتمع المدني لتوسيع الاكتشاف المبكر في كندا كلها.
- None.
- None.
Next-generation metabolomics and AI technology supports the 2026 - 2035 Pan-Canadian Lung Cancer Action Plan's call to expand equitable access to life-saving early diagnosis
Vancouver, British Columbia--(Newsfile Corp. - November 12, 2025) - November is Lung Cancer Awareness Month, and BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to support the Canadian Cancer Society's national plan to reduce lung cancer mortality in Canada by
The early detection activities and goals outlined in the 2026-2035 Pan-Canadian Lung Cancer Action Plan are highly aligned with BioMark's corporate mission of leading the world in early-stage cancer detection using metabolomics and artificial intelligence. This coordinated national effort recognizes that early detection is fundamental to saving lives and underscores the urgent need to expand access to innovative screening solutions across all Canadian communities.
"At BioMark, we believe that providing equitable, evidence-based access to early lung cancer detection will transform patient outcomes across Canada," said Rashid Bux, CEO and President, BioMark Diagnostics. "Our clinical results demonstrate the power of AI-enabled biomarker testing in identifying more early-stage cancers, even in non-smokers, directly supporting the Action Plan's commitment to saving lives nationwide. Our technology complements low-dose CT screening, addresses barriers in underserved and remote regions, and helps ensure that no Canadian is left behind in the fight against lung cancer."
The Action Plan also notes the need for innovative diagnostic tools and methods, like blood-based biomarker testing, to improve diagnostic accuracy and increase the likelihood of early-stage diagnosis. BioMark looks forward to collaborating with national partners, provincial healthcare providers, and community organizations to build capacity and make early lung cancer detection accessible, equitable, and effective across Canada. Healthcare providers and organizations interested in partnering to expand access to innovative early detection solutions are encouraged to contact BioMark.
About the Pan-Canadian Lung Cancer Action Plan
The 2026-2035 Pan-Canadian Lung Cancer Action Plan is a coordinated national strategy from the Canadian Cancer Society to reduce lung cancer mortality through improved prevention, early detection, treatment, and support. More information is available at: https://cancer.ca/en/about-us/lung-cancer-action-plan.
About BioMark Diagnostics Inc.
BioMark Diagnostics Inc. is a leading developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. BioMark is committed to developing innovative and accessible diagnostic solutions to address unmet medical needs in oncology.
Further information about BioMark is available under its profile on the SEDAR+ website www.sedarplus.ca and the CSE website https://thecse.com/.
For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-370-0779
Email: info@biomarkdiagnostics.com
Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws.
The CSE has not reviewed, approved, or disapproved of the content of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274109
FAQ
What did BioMark (BMKDF) announce on November 12, 2025 about lung cancer screening?
How does BioMark's BMKDF liquid biopsy relate to the Pan‑Canadian plan's 30% mortality reduction goal?
Does BioMark claim its BMKDF test detects lung cancer in non‑smokers?
Will BioMark (BMKDF) partner with Canadian healthcare providers to expand access?
Can BioMark's BMKDF test replace low‑dose CT screening?
How can healthcare organizations contact BioMark about partnerships after the November 12, 2025 announcement?
